Literature DB >> 19245419

Optimization of a murine immunization model for study of PF4/heparin antibodies.

S Suvarna1, R Qi, G M Arepally.   

Abstract

SUMMARY
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a life-threatening thrombotic illness caused by drug-dependent antibodies recognizing complexes of platelet factor 4 (PF4) and heparin. Little is known about the immune pathogenesis of HIT, in particular factors influencing PF4/heparin antibody formation. To gain insight into the biologic basis of heparin sensitization, we have recently developed an animal model using wild-type (WT) mice in which murine PF4/heparin antibodies (anti-mPF4/H) arise de novo after antigen challenge. OBJECTIVES AND METHODS: This report describes technical refinements to the murine model and describes additional biologic features of the immune response to mPF4/heparin.
RESULTS: Our studies indicate that antibody responses to mPF4/heparin are dependent on murine strain, injection routes and doses of mPF4 and heparin. C57BL/6 mice are more immunologically responsive to mPF4/heparin antigen than BALB/c mice and robust immunization can be achieved with intravenous, but not intraperitoneal, administration of antigen. We also observe a direct relationship between initial concentrations of mPF4 and antibody levels. Additionally, we demonstrate that mPF4/H immune response in mice decays with time, is not associated with thrombocytopenia and displays characteristics of immune recall on re-exposure to antigen.
CONCLUSIONS: These studies describe and characterize a murine model for studying the immunologic basis of PF4/heparin sensitization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19245419      PMCID: PMC3711941          DOI: 10.1111/j.1538-7836.2009.03330.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  33 in total

1.  Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia.

Authors:  B Pötzsch; W P Klövekorn; K Madlener
Journal:  N Engl J Med       Date:  2000-08-17       Impact factor: 91.245

2.  Differences in susceptibility to colonic stem cell somatic mutation in three strains of mice.

Authors:  M Kuraguchi; H Cook; E D Williams; G A Thomas
Journal:  J Pathol       Date:  2001-04       Impact factor: 7.996

3.  Temporal aspects of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

4.  The IgG subclass responses to influenza virus haemagglutinin in the mouse: effect of route of inoculation.

Authors:  M J Hocart; J S Mackenzie; G A Stewart
Journal:  J Gen Virol       Date:  1989-04       Impact factor: 3.891

5.  Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA.

Authors:  M P Reilly; S M Taylor; N K Hartman; G M Arepally; B S Sachais; D B Cines; M Poncz; S E McKenzie
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

6.  Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody.

Authors:  Zhong Q Li; Weiyi Liu; Kwang S Park; Brue S Sachais; Gowthani M Arepally; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

7.  Factors influencing the secondary antibody response to flagellin in man.

Authors:  S Whittingham; J D Buckley; I R Mackay
Journal:  Clin Exp Immunol       Date:  1978-11       Impact factor: 4.330

8.  Genetics of the antibody response to dextran in mice.

Authors:  B Blomberg; W R Geckeler; M Weigert
Journal:  Science       Date:  1972-07-14       Impact factor: 47.728

9.  Heparin-induced thrombocytopenia: laboratory studies.

Authors:  J G Kelton; D Sheridan; A Santos; J Smith; K Steeves; C Smith; C Brown; W G Murphy
Journal:  Blood       Date:  1988-09       Impact factor: 22.113

10.  Characterization of anti-acetylcholine receptor (AChR) antibodies from mice differing in susceptibility for experimental autoimmune myasthenia gravis (EAMG).

Authors:  Y M Graus; P J van Breda Vriesman; M H de Baets
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

View more
  10 in total

1.  Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH).

Authors:  M V Joglekar; P M Quintana Diez; S Marcus; R Qi; B Espinasse; M R Wiesner; E Pempe; J Liu; D M Monroe; G M Arepally
Journal:  Thromb Haemost       Date:  2012-02-08       Impact factor: 5.249

2.  Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia.

Authors:  Vincent Hayes; Ian Johnston; Gowthami M Arepally; Steven E McKenzie; Douglas B Cines; Lubica Rauova; Mortimer Poncz
Journal:  J Clin Invest       Date:  2017-02-20       Impact factor: 14.808

3.  Heparin modifies the immunogenicity of positively charged proteins.

Authors:  Shalini L Chudasama; Benjamin Espinasse; Fred Hwang; Rui Qi; Manali Joglekar; Galyna Afonina; Mark R Wiesner; Ian J Welsby; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2010-09-17       Impact factor: 22.113

Review 4.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

5.  Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4.

Authors:  Miriam E Jaax; Krystin Krauel; Thomas Marschall; Sven Brandt; Julia Gansler; Birgitt Fürll; Bettina Appel; Silvia Fischer; Stephan Block; Christiane A Helm; Sabine Müller; Klaus T Preissner; Andreas Greinacher
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

6.  Regulatory T Cells Control PF4/Heparin Antibody Production in Mice.

Authors:  Yongwei Zheng; Wen Zhu; Dipica Haribhai; Calvin B Williams; Richard H Aster; Renren Wen; Demin Wang
Journal:  J Immunol       Date:  2019-08-30       Impact factor: 5.422

7.  Critical role for mouse marginal zone B cells in PF4/heparin antibody production.

Authors:  Yongwei Zheng; Mei Yu; Andrew Podd; Liudi Yuan; Debra K Newman; Renren Wen; Gowthami Arepally; Demin Wang
Journal:  Blood       Date:  2013-03-04       Impact factor: 22.113

8.  Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model.

Authors:  Ernesto Luna; Pankaj Agrawal; Riyaz Mehta; Charlotte Vernhes; Christian Viskov; Jean Amiral; William L Warren; Donald R Drake
Journal:  Clin Appl Thromb Hemost       Date:  2014-12-18       Impact factor: 2.389

Review 9.  Cross-Species Analysis of Glycosaminoglycan Binding Proteins Reveals Some Animal Models Are "More Equal" than Others.

Authors:  Eric D Boittier; Neha S Gandhi; Vito Ferro; Deirdre R Coombe
Journal:  Molecules       Date:  2019-03-06       Impact factor: 4.411

10.  Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.

Authors:  M Margaret Prechel; Jeanine M Walenga
Journal:  Thromb J       Date:  2013-04-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.